The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …
This new report provides technological know-how of global diagnostic imaging companies. The analysis presents:
Internally developed and acquired diagnostic imaging and related technologies, including X-ray, ultrasound, MRI, CT, nuclear medicine, PET, PACS, and others.
The companies analyzed in the report include Analogic, Esaote, GE, Hitachi/Aloka, Hologic, Philips, Shimadzu, Siemens, and Toshiba